Key Market Indicators
Sales of diabetes medicine in Estonia are set to reach almost $33 million by 2026, growing at an average rate of 2.6% year on year since 2004. Estonia came in 23rd place in 2021, overtaken by Latvia with $28.71 million. Canada, Spain and Italy followed in 2nd, 3rd and 4th place respectively. Meanwhile, imports of insulin to Estonia are set to decrease from $3 million in 2021 to $1.4 million by 2026, at an average rate of 12.6% year on year since 2000. Exports of insulin from Estonia are forecast to climb to $61,510 by 2026, rising at an average rate of 2.8% year on year since 2001. Estonia came in 46th place in 2021, overtaken by Kenya with $52,560. France, Italy and China followed in 2nd, 3rd and 4th place respectively.
